Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost without AI.

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

The firm's methods - using real human tissue samples in the lab - give drug developers a more accurate picture of how their ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, W ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

Dimerix and its kidney drug is on track but with results of its phase III trial not due for years, a few more twists and turns are likely.

ASX-listed pharmaceutical companies were among the worst performers across the ASX 200 on Monday after US President Donald ...

While Quantum computing has been reported to be five years away for many years now, companies are preparing for it by setting ...

Moderna (NasdaqGS:MRNA) initiated the dosing for its innovative mRNA-4106 cancer therapy in a Phase 1 trial, signaling ongoing advancements in their oncology pipeline. However, the company's stock ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...